Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 132, Issue 2, Pages 237-245Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPJI7DEOLKCS6F
Keywords
Cancer; Circulating tumor cells; Disseminated tumor cells; HER2; Trastuzumab; Lapatinib
Categories
Ask authors/readers for more resources
Despite the advances in early detection and treatment of cancer, patients continue to die of the disease even when they seek care at an early stage. For patients with breast cancer, it is now possible to defect circulating tumor cells (CTCs) in the bloodstream and disseminated tumor cells (DTCs) in the bone marrow by using immunocytochemical and molecular methods. CTCs and DTCs have been found to share similar genotypic and phenotypic characteristics with so-called breast cancer stem cells, a finding that could potentially explain the eventual relapse of disease in a patient previously considered to have been cured by primary therapy. In some studies, the presence of CTCs or DTCs at the time of diagnosis of breast cancer is an independent adverse prognostic variable. However, before CTC/DTC testing can achieve standard-of-care status, there must be improvement in the sensitivity, precision, and reproducibility of the detection methods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available